Cathepsins and their endogenous inhibitors cystatins: Expression and modulation in multiple sclerosis

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 11, 2011, Pages 2421-2429

  Haves Zburof, Dana ^a   Paperna, Tamar ^a   Gour Lavie, Alumit ^a   Mandel, Ilana ^a   Glass Marmor, Lea ^a   Miller, Ariel ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

Author keywords

Biomarker; Cystein protease; Glucocorticoids; Interferon ; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; CATHEPSIN; CATHEPSIN B; CATHEPSIN S; CYSTATIN B; CYSTATIN C; MESSENGER RNA; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; BIOSYNTHESIS; BLOOD; CYTOLOGY; DISEASE COURSE; DRUG ANTAGONISM; FEMALE; HUMAN; LEUKOCYTE; MALE; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS; PATHOLOGY;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CATHEPSIN B; CATHEPSINS; CYSTATIN B; CYSTATIN C; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-BETA; LEUKOCYTES; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS; RNA, MESSENGER;

EID: 80054899016     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01229.x     Document Type: Article

References (53)

1. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease Ann Neurol. 2009; 65: 239-48.
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372: 1502-17.
3. Chandler S, Miller KM, Clements JM, et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol. 1997; 72: 155-61.
4. Agrawal SM, Lau L, Yong VW. MMPs in the central nervous system: where the good guys go bad. Semin Cell Dev Biol. 2008; 19: 42-51.
5. Galboiz Y, Shapiro S, Lahat N, et al. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol. 2001; 50: 443-51.
6. Stahn C, Lowenberg M, Hommes DW, et al Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol. 2007; 275: 71-8.
7. Yong VW, Zabad RK, Agrawal S, et al. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci. 2007; 259: 79-84.
8. Glass-Marmor L, Paperna T, Galboiz Y, et al Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses. J Neuroimmunol. 2009; 210: 124-7.
9. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010; 74: S17-24.
10. Brix K, Dunkhorst A, Mayer K, et al Cysteine cathepsins: cellular roadmap to different functions. Biochimie. 2008; 90: 194-207.
11. Burster T, Beck A, Tolosa E, et al. Differential processing of autoantigens in lysosomes from human monocyte-derived and peripheral blood dendritic cells. J Immunol. 2005; 175: 5940-9.
12. Zavasnik-Bergant T, Turk B. Cysteine proteases: destruction ability versus immunomodulation capacity in immune cells. Biol Chem. 2007; 388: 1141-9.
13. Hsing LC, Rudensky AY. The lysosomal cysteine proteases in MHC class II antigen presentation. Immunol Rev. 2005; 207: 229-41.
14. Faure-Andre G, Vargas P, Yuseff MI, et al. Regulation of dendritic cell migration by CD74, the MHC class II-associated invariant chain. Science. 2008; 322: 1705-10.
15. Lutgens SP, Cleutjens KB, Daemen MJ, et al Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 2007; 21: 3029-41.
16. Flannery T, Gibson D, Mirakhur M, et al. The clinical significance of cathepsin S expression in human astrocytomas. Am J Pathol. 2003; 163: 175-82.
17. Hao HP, Doh-Ura K, Nakanishi H. Impairment of microglial responses to facial nerve axotomy in cathepsin S-deficient mice. J Neurosci Res. 2007; 85: 2196-206.
18. Gillet L, Roger S, Besson P, et al. Voltage-gated sodium channel activity promotes cysteine cathepsin-dependent invasiveness and colony growth of human cancer cells. J Biol Chem. 2009; 284: 8680-91.
19. Conus S, Simon HU. Cathepsins: key modulators of cell death and inflammatory responses. Biochem Pharmacol. 2008; 76: 1374-82.
20. Yang H, Kala M, Scott BG, et al. Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis. J Immunol. 2005; 174: 1729-37.
21. Saegusa K, Ishimaru N, Yanagi K, et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest. 2002; 110: 361-9.
22. Katunuma N, Matsunaga Y, Himeno K, et al Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors. Biol Chem. 2003; 384: 883-90.
23. Vasiljeva O, Reinheckel T, Peters C, et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des. 2007; 13: 387-403.
24. Pozgan U, Caglic D, Rozman B, et al. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem. 2010; 391: 571-9.
25. Beck H, Schwarz G, Schroter CJ, et al. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur J Immunol. 2001; 31: 3726-36.
26. Bever CT Jr, Garver DW. Increased cathepsin B activity in multiple sclerosis brain. J Neurol Sci. 1995; 131: 71-3.
27. Bever CT Jr, Panitch HS, Johnson KP. Increased cathepsin B activity in peripheral blood mononuclear cells of multiple sclerosis patients. Neurology. 1994; 44: 745-8.
28. Nagai A, Murakawa Y, Terashima M, et al. Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Neurology. 2000; 55: 1828-32.
29. Ma J, Tanaka KF, Yamada G, et al Induced expression of cathepsins and cystatin C in a murine model of demyelination. Neurochem Res. 2007; 32: 311-20.
30. Grossman I, Avidan N, Singer C, et al. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet Genomics. 2007; 17: 657-66.
31. Cunningham S, Graham C, Hutchinson M, et al. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther. 2005; 78: 635-46.
32. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50: 121-7.
33. Glass-Marmor L, Paperna T, Ben-Yosef Y, et al Chronotherapy using corticosteroids for multiple sclerosis relapses. J Neurol Neurosurg Psychiatry. 2007; 78: 886-8.
34. Byun E, Caillier SJ, Montalban X, et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol. 2008; 65: 337-44.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402-8.
36. Zavasnik-Bergant T, Turk B. Cysteine cathepsins in the immune response. Tissue Antigens. 2006; 67: 349-55.
37. Liu J, Ma L, Yang J, et al. Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis. 2006; 186: 411-9.
38. Riese RJ, Mitchell RN, Villadangos JA, et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest. 1998; 101: 2351-63.
39. Hansson SF, Simonsen AH, Zetterberg H, et al. Cystatin C in cerebrospinal fluid and multiple sclerosis. Ann Neurol. 2007; 62: 193-6.
40. Irani DN, Anderson C, Gundry R, et al. Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol. 2006; 59: 237-47.
41. Liu S, Bai S, Qin Z, et al. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J Cell Mol Med. 2009; 13: 1586-603.
42. Bjarnadottir M, Grubb A, Olafsson I. Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest. 1995; 55: 617-23.
43. Cimerman N, Brguljan PM, Krasovec M, et al. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta. 2000; 300: 83-95.
44. Cimerman N, Brguljan PM, Krasovec M, et al. Circadian and concentration profile of cathepsin S in sera from healthy subjects and asthmatic patients. Pflugers Arch. 2001; 442: R204-6.
45. Costantino CM, Ploegh HL, Hafler DA. Cathepsin S regulates class II MHC processing in human CD4+ HLA-DR+ T cells. J Immunol. 2009; 183: 945-52.
46. Tischner D, Reichardt HM. Glucocorticoids in the control of neuroinflammation. Mol Cell Endocrinol. 2007; 275: 62-70.
47. Staun-Ram E, Miller A. Cathepsins (S and B) and their inhibitor cystatin C in immune cells: modulation by interferon-β and role played in cell migration. J Neuroimmunol. 2010; doi.
48. Shi GP, Webb AC, Foster KE, et al. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem. 1994; 269: 11530-6.
49. Wang B, Sun J, Kitamoto S, et al. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem. 2006; 281: 6020-9.
50. Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle. 2007; 6: 60-4.
51. Bar-Or A, Nuttall RK, Duddy M, et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain. 2003; 126: 2738-49.
52. Lindberg RL, De Groot CJ, Montagne L, et al. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain. 2001; 124: 1743-53.
53. Leppert D, Lindberg RL, Kappos L, et al Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev. 2001; 36: 249-57.